McKesson Croissance future
Future contrôle des critères 2/6
McKesson devrait augmenter ses bénéfices et son chiffre d'affaires de 8.7% et de 6.8% par an respectivement. Le BPA devrait croître de de 12.1% par an. Le rendement des capitaux propres devrait être 138.8% dans 3 ans.
Informations clés
8.7%
Taux de croissance des bénéfices
12.06%
Taux de croissance du BPA
| Healthcare croissance des bénéfices | 18.3% |
| Taux de croissance des recettes | 6.8% |
| Rendement futur des capitaux propres | 138.76% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 13 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • May 13
MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal
Analysts have trimmed the McKesson fair value estimate by about $39 to $951.73. This reflects updated views on slightly higher discount rates, a more moderate revenue growth outlook, a small shift in profit margin assumptions, and a lower future P/E multiple after a mix of recent price target increases and cuts across the Street.Article d’analyse • May 11
McKesson Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
McKesson Corporation ( NYSE:MCK ) shareholders are probably feeling a little disappointed, since its shares fell 8.9...Seeking Alpha • May 01
McKesson - "Hold" Still Valid In 2026
Summary McKesson (MCK) is a fundamentally strong, market-leading distributor but faces mounting structural risks in the US healthcare sector. I see current valuation—over 21x P/E—as unattractive, with upside limited by regulatory, pricing, and margin pressures. Much of MCK's recent growth stems from high-priced drugs and GLP-1 revenues, which may plateau and expose underlying business vulnerabilities. I assign MCK a 'Hold' rating with a $510/share price target, citing insufficient risk/reward at present levels. Read the full article on Seeking AlphaMise à jour du récit • Apr 27
MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal
McKesson's analyst price target has been trimmed slightly, with the fair value estimate edging down by about $1 to $990.87 as analysts factor in recent target cuts alongside ongoing interest in the company's biosimilar and distribution opportunities. Analyst Commentary Recent research on McKesson has centered on how much value the market is assigning to its biosimilar pipeline, distribution scale and perceived defensiveness within healthcare, with a mix of higher and lower price targets reflecting different views on execution risk and current valuation.Mise à jour du récit • Apr 10
MCK: Biosimilar Co Manufacturing Optionality Will Shape Future Safe Haven Appeal
McKesson's analyst-derived fair value estimate has been adjusted slightly lower, from about $997.67 to $991.67. Analysts are weighing recent trims to Street price targets and fresh caution around premium valuation against prior enthusiasm for biosimilar optionality and healthcare defensiveness.Mise à jour du récit • Mar 27
MCK: Biosimilar And Co Manufacturing Upside Will Shape Future Safe Haven Returns
Analysts have nudged the McKesson fair value estimate slightly higher to about $998, citing a wave of Street price target increases into the $1,040 to $1,050 range and growing focus on potential upside from biosimilars and co-manufacturing. Analyst Commentary Recent Street research around McKesson clusters around two themes: valuation and execution on new growth levers such as biosimilars and co-manufacturing.Mise à jour du récit • Mar 11
MCK: Biosimilar Optionality And Premium Safe Haven Position Will Shape Future Returns
Analysts have increased their McKesson price target from $980.40 to $995.27, citing higher Street targets that reflect new biosimilar optionality and continued interest in the stock as a perceived healthcare safe haven, even at a premium valuation. Analyst Commentary Bullish analysts are leaning into McKesson's role as a perceived healthcare safe haven and the new biosimilar angle, using these themes to justify higher valuation levels than the recent three year average.Mise à jour du récit • Feb 24
MCK: Defensive Healthcare Premium And Buybacks Will Shape Perceived Safety Trade
Analysts have raised McKesson's fair value estimate by about $14 to $980.40, as a series of higher Street price targets, including Barclays' move to $1,050, keeps the stock in focus for investors seeking perceived safety within healthcare, even as shares trade at a premium to recent averages. Analyst Commentary Recent research has centered on McKesson's valuation after a series of price target increases, including a move to US$1,050 that highlights how closely investors are watching the name as a perceived defensive healthcare holding.Mise à jour du récit • Feb 09
MCK: Refined Assumptions And Supportive Policy Backdrop Will Shape FY26 AOI
The McKesson analyst price target has been raised by about $24 to $966, with analysts pointing to updated fair value work, modest adjustments to the discount rate and growth assumptions, and slightly higher future P/E expectations as key drivers of the change. Analyst Commentary Recent Street research on McKesson clusters around higher price targets and refreshed valuation work, with analysts fine tuning assumptions on growth, discount rates and future P/E multiples.Mise à jour du récit • Jan 26
MCK: North American Pharma Momentum And Supportive Policy Backdrop Will Drive FY26 AOI
Narrative Update The analyst price target for McKesson has been raised by roughly $3 to $942.00, as analysts point to steady assumptions for revenue growth, margins and P/E, along with supportive views on North American Pharma momentum, a constructive industry demand backdrop, and the absence of new onerous proposals in recent healthcare policy commentary. Analyst Commentary Recent research on McKesson is broadly constructive, with several firms lifting their price targets and pointing to supportive sector trends and company specific drivers.Mise à jour du récit • Jan 12
MCK: North American Pharma Strength Will Support FY26 Core AOI Framework
Narrative Update: McKesson Analysts have lifted their McKesson price targets toward a range of about $900 to $1,000, citing solid North American Pharma momentum, modeled core AOI growth of around 7% for FY26, and a robust demand backdrop reflected in peers' recent results. Analyst Commentary Recent research updates reflect a more constructive stance on McKesson, with higher price targets tied to underlying business trends and peer readthroughs rather than short term trading factors.Mise à jour du récit • Dec 18
MCK: North American Pharma Momentum Will Drive Future EPS Framework Confidence
Our McKesson narrative fair value has increased modestly to approximately $939 per share from about $935, reflecting analysts' higher price targets and conviction in sustained EPS growth, improved North American Pharma momentum, and a more robust valuation framework supported by stronger industry demand trends. Analyst Commentary Street research sentiment on McKesson remains skewed positive, with a broad wave of price target increases reflecting higher conviction in the companys ability to deliver on its upgraded long term earnings framework and FY26 guidance.Mise à jour du récit • Dec 03
MCK: North American Pharma Momentum Will Drive Future Outlook Amid Policy Uncertainty
We modestly raise our McKesson fair value estimate to about $934.79 per share from roughly $934.71, reflecting analysts' higher price targets, stronger confidence in long term EPS growth, and sustained North American Pharma momentum. Analyst Commentary Street research on McKesson has turned increasingly constructive, with multiple firms lifting price targets in response to upgraded long term guidance, stronger segment momentum, and enhanced disclosure following the recent investor day.Mise à jour du récit • Nov 19
MCK: Future Execution and Pharma Trends Will Shape Outlook Amid Policy Uncertainty
McKesson's analyst price target has been raised significantly, increasing by nearly $90 per share to $934.71. Analysts cite strong momentum in North American Pharma, higher long-term EPS guidance, and robust industry trends supporting continued growth.Mise à jour du récit • Nov 05
MCK: Future Demand and Oncology Distribution Will Set the Earnings Outlook
McKesson’s analyst price target has increased from approximately $837 to $845. Analysts cite robust demand, industry-wide utilization trends, and the company’s strengthened long-term earnings outlook as key factors supporting the upward revision.Mise à jour du récit • Oct 22
Analysts Boost McKesson Outlook Amid Strong Growth Guidance and Recent Valuation Adjustments
Analysts have raised their average fair value estimate for McKesson to $836.71 from $829.57. This change is attributed to increased long-term growth guidance and improved business visibility following the company’s recent investor day.Mise à jour du récit • Oct 08
Pharmaceutical Demand And Digital Automation Will Shape Future Markets
McKesson's analyst fair value estimate has been raised from $793.21 to $829.57. This increase reflects higher price targets, driven by analysts who cite upgraded long-term growth guidance and strengthened expectations following recent investor presentations.Mise à jour du récit • Sep 24
Pharmaceutical Demand And Digital Automation Will Shape Future Markets
McKesson’s fair value saw only a marginal increase as analyst expectations for both revenue growth and net profit margin remained virtually unchanged, with the target price moving slightly from $788.57 to $793.21. What's in the News Playhouse MD™, a pediatric healthcare brand, has entered a strategic distribution alliance with McKesson Medical-Surgical, making its products available nationwide and expanding McKesson's portfolio in pediatric care.Article d’analyse • Jul 07
Why Investors Shouldn't Be Surprised By McKesson Corporation's (NYSE:MCK) P/E
With a price-to-earnings (or "P/E") ratio of 27.3x McKesson Corporation ( NYSE:MCK ) may be sending bearish signals at...Seeking Alpha • Mar 25
McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025
Summary I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue growing 45% year-over-year and oncology patient visits increasing steadily. Despite potential tariff-related risks in the biotech sector, McKesson's strong performance and strategic guidance make it a safe haven for investors in 2025. Read the full article on Seeking AlphaSeeking Alpha • Jan 21
McKesson Seems Cheap, But Risks Linger
Summary McKesson's stock appears undervalued, trading at 18 times forward earnings and free cash flow, despite recent price increases and solid growth prospects in oncology and GLP-1 medications. Quarterly results show mixed performance, with revenue up 21.3% YoY but operating income and EPS down; adjusted EPS grew 13.5% YoY. Risks include political pressures on drug pricing, competition from vertically integrated healthcare providers like CVS and Amazon, and potential recession impacts. Despite bullish arguments and recession resilience, I rate McKesson as a 'Hold' due to high recession risk and a cautious market outlook. Read the full article on Seeking AlphaSeeking Alpha • Nov 09
McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
Summary I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% interest in Florida Cancer Specialists enhances its oncology network, expanding to 3,300 providers across 31 states. Strong Q2 results with 21% revenue growth and raised EPS guidance to $32.40-$33.00, driven by specialty distribution and retail national account customers. Future growth driven by GLP-1 medications, oncology network expansion, and margin improvements, despite weak growth in Medical surgical solutions post-Covid. Read the full article on Seeking AlphaSeeking Alpha • Oct 09
McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
Summary Healthcare is a great defensive sector that has lower amounts of cyclicality than others that depend on the booming economy. With the stock currently down -21.44% off of its all-time high, the stock is giving investors a nice entry point as it reverts to the mean S&P500 returns. The company was the highest-scoring large cap on the most recent Magic Formula screen for October 2024. The Healthcare distribution sub-sector provides exposure to big Pharma without the patent cliffs. Read the full article on Seeking AlphaSeeking Alpha • Sep 10
McKesson: The Correction Is Not Over
Summary McKesson declined about 20% in the last few weeks and sentiment suddenly turned. Of course, McKesson is performing hand-in-hand with the overall market and we can expect that McKesson will continue to decline - similar to the overall market. On the other hand, we can argue that McKesson is already undervalued a bit, but I still think the stock will continue to decline further due to the overall sentiment. Read the full article on Seeking AlphaSeeking Alpha • Jul 04
McKesson Corporation: An Interesting Health Giant With A Hidden Gem
Summary McKesson Corporation is a large player in the medical space, with a market capitalization of $75.86 billion. The company has shown attractive top-line growth, but bottom-line results have been disappointing. The most interesting segment of the business is the Prescription Technology Solutions segment, showing impressive growth and profitability. Read the full article on Seeking AlphaPrévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 3/31/2029 | 499,325 | 6,051 | 6,554 | 7,469 | 11 |
| 3/31/2028 | 463,939 | 5,424 | 6,098 | 7,014 | 15 |
| 3/31/2027 | 431,646 | 4,926 | 4,687 | 5,543 | 15 |
| 3/31/2026 | 403,430 | 4,762 | 5,410 | 6,155 | N/A |
| 12/31/2025 | 397,958 | 4,340 | 9,644 | 10,482 | N/A |
| 9/30/2025 | 387,094 | 4,033 | 6,008 | 6,867 | N/A |
| 6/30/2025 | 377,595 | 3,164 | 5,666 | 6,547 | N/A |
| 3/31/2025 | 359,051 | 3,295 | 5,226 | 6,085 | N/A |
| 12/31/2024 | 344,583 | 2,826 | 1,634 | 2,484 | N/A |
| 9/30/2024 | 330,187 | 2,536 | 4,313 | 5,121 | N/A |
| 6/30/2024 | 313,751 | 2,959 | 3,256 | 3,986 | N/A |
| 3/31/2024 | 308,951 | 3,002 | 3,627 | 4,314 | N/A |
| 12/31/2023 | 301,506 | 2,998 | 2,892 | 3,492 | N/A |
| 9/30/2023 | 291,098 | 3,487 | 4,306 | 4,906 | N/A |
| 6/30/2023 | 284,040 | 3,755 | 4,466 | 5,048 | N/A |
| 3/31/2023 | 276,711 | 3,563 | 4,601 | 5,159 | N/A |
| 12/31/2022 | 273,903 | 3,146 | 4,190 | 4,721 | N/A |
| 9/30/2022 | 272,027 | 2,061 | 3,952 | 4,430 | N/A |
| 6/30/2022 | 268,446 | 1,396 | 4,639 | 5,115 | N/A |
| 3/31/2022 | 263,966 | 1,119 | 3,899 | 4,434 | N/A |
| 12/31/2021 | 257,006 | 1,415 | 4,323 | 4,917 | N/A |
| 9/30/2021 | 250,991 | -4,804 | 4,098 | 4,753 | N/A |
| 6/30/2021 | 245,223 | -4,494 | 3,299 | 3,982 | N/A |
| 3/31/2021 | 238,228 | -4,538 | 3,901 | 4,542 | N/A |
| 12/31/2020 | 237,621 | -4,189 | 5,231 | 5,826 | N/A |
| 9/30/2020 | 234,194 | 2,228 | 3,905 | 4,492 | N/A |
| 6/30/2020 | 231,002 | 922 | 2,851 | 3,363 | N/A |
| 3/31/2020 | 231,051 | 906 | 3,868 | 4,374 | N/A |
| 12/31/2019 | 224,945 | -905 | N/A | 3,615 | N/A |
| 9/30/2019 | 221,981 | -626 | N/A | 3,559 | N/A |
| 6/30/2019 | 217,440 | 601 | N/A | 5,046 | N/A |
| 3/31/2019 | 214,319 | 33 | N/A | 4,036 | N/A |
| 12/31/2018 | 213,518 | -319 | N/A | 3,165 | N/A |
| 9/30/2018 | 210,927 | 113 | N/A | 3,324 | N/A |
| 6/30/2018 | 209,913 | -384 | N/A | 2,543 | N/A |
| 3/31/2018 | 208,357 | 62 | N/A | 4,345 | N/A |
| 12/31/2017 | 205,442 | 4,805 | N/A | 2,756 | N/A |
| 9/30/2017 | 201,955 | 4,539 | N/A | 3,155 | N/A |
| 6/30/2017 | 199,851 | 4,846 | N/A | 3,626 | N/A |
| 3/31/2017 | 198,533 | 5,194 | N/A | 4,744 | N/A |
| 12/31/2016 | 196,498 | 2,051 | N/A | 6,415 | N/A |
| 9/30/2016 | 194,267 | 2,044 | N/A | 5,349 | N/A |
| 6/30/2016 | 193,071 | 2,359 | N/A | 5,077 | N/A |
| 3/31/2016 | 190,884 | 2,290 | N/A | 3,672 | N/A |
| 12/31/2015 | 189,131 | 2,237 | N/A | 2,449 | N/A |
| 9/30/2015 | 187,716 | 2,090 | N/A | 4,198 | N/A |
| 6/30/2015 | 183,115 | 1,950 | N/A | 3,384 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de MCK ( 8.7% par an) est supérieure au taux d'épargne ( 3.5% ).
Bénéfices vs marché: Les bénéfices de MCK ( 8.7% par an) devraient croître plus lentement que le marché US ( 16.7% par an).
Croissance élevée des bénéfices: Les bénéfices de MCK devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de MCK ( 6.8% par an) devrait croître plus lentement que le marché de US ( 11.7% par an).
Croissance élevée des revenus: Le chiffre d'affaires de MCK ( 6.8% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de MCK devrait être très élevé dans 3 ans ( 138.8 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 04:27 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
McKesson Corporation est couverte par 33 analystes. 15 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Toung | Argus Research Company |
| Eric Coldwell | Baird |
| Lawrence Marsh | Barclays |